Epperly Melissa B, Increases Stake in NAUT
Epperly Melissa B, bought 45,000 shares of NAUT on June 18, 2026.
Key Points
- Epperly Melissa B, bought 45,000 shares of NAUT on June 18, 2026, as part of an insider transaction.
- Shares of NAUT traded at $2.31 on Tuesday, with recent insider purchases by multiple executives.
- Guggenheim maintained a 'buy' rating with a $4.00 target, while Goldman Sachs downgraded to 'sell'.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Epperly Melissa B, made a notable move by purchasing 45,000 shares of NAUT on June 18, 2026. This insider transaction did not occur under a planned trading program.
Insider Buying and Selling at Nautilus Biotechnology, Inc.
On June 18, 2026, several insiders, including Epperly Melissa B,, Matthew McIlwain, Matthew Posard, Karen Akinsanya, Farzad Nazem, and Sujal Patel, increased their holdings in NAUT. Each of these insiders, except for Patel, acquired 45,000 shares. Sujal Patel, who serves as the CEO, President, and Secretary, bought 25,000 shares earlier on March 4, 2026, at an average price of $2.61.
Other Institutional Activity in NAUT
Several institutional investors have shown interest in NAUT. A16Z Capital Management, L.L.C. holds 17,653,917 shares valued at approximately $68.5 million. Perceptive Advisors LLC maintains its position with 12,594,211 shares worth about $48.9 million. Similarly, Cercano Management LLC holds 7,172,985 shares valued at $27.8 million. Meanwhile, Vanguard Capital Management LLC and Clearstead Advisors, LLC have both opened new positions, holding 2,545,597 and 2,329,784 shares, respectively.
Analysts Set New Price Targets
On February 27, 2026, Guggenheim maintained its 'buy' rating for NAUT, setting a price target of $4.00. Previously, on December 8, 2024, Goldman Sachs downgraded the stock to a 'sell' with a target of $1.75. Morgan Stanley has maintained a 'hold' rating with a price target of $5.00 since July 31, 2024.
Bottom Line
The recent insider buying activity at NAUT, including significant purchases by several executives, suggests confidence in the company's future. Investors often track such transactions for potential insights, though they are backward-looking and may not reflect current positions. Analyst ratings also offer varied perspectives, with Guggenheim's optimistic outlook contrasting with Goldman Sachs' more cautious stance.
Get Nautilus Biotechnology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NAUT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.